NASDAQ$BNGO
BioNano Genomics Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Bionano Genomics reported a decrease in revenue and an increase in net loss compared to the same period last year.
Bionano Genomics reported a decrease in total revenue for the fourth quarter of 2019, with a significant decrease in instrument revenue offset by an increase in consumable revenue. The company's net loss increased, attributed to higher operating expenses. Despite the financial results, the company highlighted the growing acceptance and recognition of their Saphyr system.
- Total revenue decreased by 31% to $2.8 million compared to Q4 2018.
- Instrument revenue decreased by 50% to $1.5 million.
- Consumable revenue increased by 35% to $1.1 million.
- Net loss increased to $7.9 million compared to $6.4 million in Q4 2018.
Headline financials
Revenue & EPS history
BioNano · Revenue · Quarterly
$2.79M
Revenue by segment
BioNano · $2.79M total across 2 segments · Q4 2019
- Product Revenue$2.6M—93.4%
- Service and Other Revenue$185K—6.6%
Forward guidance
This press release contains forward-looking statements regarding trends in the adoption of the Saphyr system, beliefs regarding near-term shifts towards broader adoption, and efforts to execute commercial strategy. These statements involve risks and uncertainties, and actual results may differ materially.
Tailwinds
- Expectations regarding trends in the adoption of the Saphyr system
- Beliefs regarding near-term shifts towards broader adoption of the Saphyr system
- Efforts to execute on commercial strategy
- Focus on accelerating the search for new diagnostics and therapeutic targets
- Drive the adoption of digital cytogenetics
Headwinds
- General market conditions
- Changes in the competitive landscape and the introduction of competitive products
- Changes in strategic and commercial plans
- Ability to obtain sufficient financing to fund strategic plans and commercialization efforts
- Loss of key members of management and commercial team
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2019
-3.3%
Avg return
Earnings day
-5.4%
Avg return
5 days after
-7.7%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+15.5%
Q4 2018
Best reaction
-29.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | +1.6% | — | |
| Q1 2026 | -0.8% | -9.5% | -7.9% | |
| Q3 2025 | +2.8% | +4.8% | +10.2% | |
| Q1 2025 | +2.9% | +0.8% | -2.4% | |
| Q4 2024 | +11.1% | +8.6% | +43.4% | |
| Q3 2024 | -3.4% | -11.5% | -7.7% | |
| Q2 2024 | -21.5% | -23.5% | -13.7% | |
| Q1 2024 | +2.7% | +7.3% | -9.4% | |
| Q4 2023 | +0.0% | -5.8% | -18.2% | |
| Q3 2023 | -7.0% | -10.5% | +2.8% | |
| Q2 2023 | -0.2% | -13.9% | -15.7% | |
| Q1 2023 | +6.9% | -9.6% | +0.0% | |
| Q4 2022 | -8.4% | -5.3% | -19.8% | |
| Q3 2022 | +2.7% | +2.2% | -6.3% | |
| Q2 2022 | +6.6% | +0.0% | +2.2% | |
| Q1 2022 | -16.1% | -24.2% | -10.8% | |
| Q4 2021 | +1.4% | -10.7% | +20.6% | |
| Q3 2021 | -9.8% | -13.7% | -44.4% | |
| Q2 2021 | +5.4% | +4.4% | -1.0% | |
| Q1 2021 | +13.9% | +22.8% | +59.9% | |
| Q4 2020 | -17.9% | -14.4% | -34.1% | |
| Q3 2020 | -7.4% | -5.4% | -10.7% | |
| Q2 2020 | -8.4% | -6.5% | -32.5% | |
| Q1 2020 | -8.4% | -11.8% | +21.6% | |
| Q4 2019 | -29.8% | -30.3% | -74.3% | |
| Q3 2019 | -2.1% | +17.8% | +24.4% | |
| Q2 2019 | -14.4% | -11.3% | -50.5% | |
| Q1 2019 | -11.3% | -17.0% | -28.1% | |
| Q4 2018 | +15.5% | +7.4% | -8.1% | |
| Q3 2018 | -6.0% | -5.7% | -11.9% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro